HDACi delivery reprograms tumor-infiltrating myeloid cells to eliminate antigen-loss variants
Open accessAbstract
Immune recognition of tumor-expressed antigens by cytotoxic CD8 + T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination can be prevented using class I HDACi, MS-275. Drug delivery subverted the phenotype of tumor-infiltrating CD11b + Ly6C hi Ly6G – myeloid cells, favoring NOS2/ROS secretion and pro-inflammatory genes characteristic of M1 polarization. Simultaneously, MS-275 abrogated the immunosuppressive function of tumor-infiltrating myeloid cells and reprogrammed them to eliminate antigen-negative tumor cells in a caspase-dependent manner. Elevated IFN-γ within the tumor microenvironment suggests that MS-275 modulates the local cytokine landscape to favor antitumor myeloid polarization through the IFN-γR/STAT1 signaling axis. Exploiting tumor-infiltrating myeloid cell plasticity thus complements T cell therapy in targeting tumor heterogeneity and immune escape.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Simply abrogating class I HDAC activity without interference with other epigenetic regulators is sufficient to influence expression of cytokines, chemokines, and other inflammatory signals that remodel immune cell activities.
“Simply abrogating class I HDAC activity without any interference with other epigenetic regulators is sufficient to influence the expression of cytokines, chemokines, and other inflammatory signals that remodel immune cells activities (Hicks et al., 2020;Hicks et al., 2021;Nguyen et al., 2018).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Nguyen et al., 2018
In the presence of entinostat, increased IFN-γ levels in the tumor microenvironment modulate the local cytokine landscape and promote antitumor myeloid polarization.
“In the presence of entinostat, increased IFN-γ levels in the tumor microenvironment modulate the local cytokine landscape and promote antitumor myeloid polarization (Nguyen et al., 2018).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Nguyen et al., 2018
Entinostat can suppress the immunosuppressive effect of tumor-infiltrating myeloid cells and reprogram them to eliminate antigen-negative tumor cells.
“Entinostat can suppress the immunosuppressive effect of tumorinfiltrating myeloid cells and reprogram them to eliminate antigennegative tumor cells.”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Nguyen et al., 2018
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · see citing works
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603 · see citing works
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,221 · see citing works
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · see citing works
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L. E., Worthen, G. S., & Albelda, S. Μ. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,382 · see citing works
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works
Haberland, M., Montgomery, R. L., & Olson, E. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,541 · see citing works
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · see citing works
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · see citing works
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,035 · see citing works
lumi : a pipeline for processing Illumina microarray
Du, P., Kibbe, W. A., & Lin, S. M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn224 · Cited by 2,028 · see citing works
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · see citing works
Modulation of macrophage phenotype by cell shape
McWhorter, F. Y., Wang, T., Nguyen, P., Chung, T., & Liu, W. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308887110 · Cited by 1,482 · see citing works
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428 · see citing works
Macrophage Polarization in Bacterial Infections
Benoit, M. E., Desnues, B., & Mège, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3733 · Cited by 1,317 · see citing works
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · see citing works
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074 · see citing works
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,054 · see citing works
The roles of IFNγ in protection against tumor development and cancer immunoediting
Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00038-7 · Cited by 899 · see citing works
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Henau, O. D., Rausch, M. P., Winkler, D. A., Campesato, L. F., Liu, C., Hirschhorn-Cymerman, D., Budhu, S., Ghosh, A., Pink, M. M., Tchaicha, J. H., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 862 · see citing works
Ahmed, R., Salmi, A. A., Butler, L. D., Chiller, J. M., & Oldstone, M. B. A. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.2.521 · Cited by 792 · see citing works
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788 · see citing works
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Sirokay, J. D., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 635 · see citing works
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 617 · see citing works
Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000901 · Cited by 582 · see citing works
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578 · see citing works
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lü, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 550 · see citing works
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546 · see citing works
Activation of the STAT Signaling Pathway Can Cause Expression of Caspase 1 and Apoptosis
Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., & Fu, X.-Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5328 · Cited by 521 · see citing works
Model-based variance-stabilizing transformation for Illumina microarray data
Lin, S. M., Du, P., Huber, W. K., & Kibbe, W. A. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1075 · Cited by 515 · see citing works
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481 · see citing works
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 463 · see citing works
Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
Bloom, M. B., Perry-Lalley, D. M., Robbins, P. F., Li, Y., El‐Gamil, M., Rosenberg, S. A., & Yang, J. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.453 · Cited by 401 · see citing works
Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy
Hanson, H. L., Donermeyer, D. L., Ikeda, H., White, J. M., Shankaran, V., Old, L. J., Shiku, H., Schreiber, R. D., & Allen, P. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00026-1 · Cited by 358 · see citing works
Umemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G., Okada, M., Balázs, M., Ádány, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 347 · see citing works
Production and Detection of Reactive Oxygen Species (ROS) in Cancers
Wu, D., & Yotnda, P. (2011) · Journal of Visualized Experiments · doi:10.3791/3357 · Cited by 278 · see citing works
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., et al. (2017) · Nature · doi:10.1038/nature22311 · Cited by 271 · see citing works
Quah, B., & Parish, C. R. (2010) · Journal of Visualized Experiments · doi:10.3791/2259 · Cited by 211 · see citing works
Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk
Piccolo, V., Curina, A., Genua, M., Ghisletti, S., Simonatto, M., Sabò, A., Amati, B. B., Ostuni, R., & Natoli, G. (2017) · Nature Immunology · doi:10.1038/ni.3710 · Cited by 209 · see citing works
RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis
Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G. J., Morlacchi, S., Totaro, M. G., Porta, C., Anselmo, A., Tartari, S., Doni, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.006 · Cited by 204 · see citing works
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 204 · see citing works
Interpretation of cellular proliferation data: Avoid the panglossian
Roederer, M. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21010 · Cited by 198 · see citing works
Potentiating Cancer Immunotherapy Using an Oncolytic Virus
Bridle, B. W., Stephenson, K. B., Boudreau, J. E., Koshy, S. T., Kazdhan, N., Pullenayegum, E., Brunellière, J., Bramson, J. L., Lichty, B. D., & Wan, Y. (2010) · Molecular Therapy · doi:10.1038/mt.2010.98 · Cited by 176 · see citing works
Ma, G., Pan, P., Eisenstein, S. G., Divino, C. M., Lowell, C. A., Takai, T., & Chen, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.004 · Cited by 175 · see citing works
Maraba Virus as a Potent Oncolytic Vaccine Vector
Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S. J., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.249 · Cited by 173 · see citing works
Prévost‐Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M., & Pircher, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2187 · Cited by 172 · see citing works
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Takeda, K., NAKAYAMA, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D. M., & Smyth, M. J. (2017) · Nature Communications · doi:10.1038/ncomms14607 · Cited by 156 · see citing works
In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory site
Haverkamp, J. M., Crist, S. A., Elzey, B. D., Bozkus, C. C., & Ratliff, T. L. (2011) · European Journal of Immunology · doi:10.1002/eji.201041069 · Cited by 133 · see citing works
Morphological evaluation of monocytes and their precursors
Goasguen, J.-E., Bennett, J. M., Bain, B. J., Vallespı́, T., Brunning, R. D., Mufti, G. J., & for the International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) (2009) · Haematologica · doi:10.3324/haematol.2008.005421 · Cited by 125 · see citing works
Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J., Pol, J. G., Nguyen, A., Capretta, A. A., He, R., Bramson, J. L., Bell, J. C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.265 · Cited by 109 · see citing works
Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
Ikeda, H., Ohta, N., Furukawa, K., Miyazaki, H., Wang, L., Furukawa, K., Kuribayashi, K., Old, L. J., & Shiku, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6375 · Cited by 99 · see citing works
Myeloid-derived suppressor cells in transplantation and cancer
Ochando, J., & Chen, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8335-1 · Cited by 86 · see citing works
López‐Castejón, G., Baroja‐Mazo, A., & Pelegrı́n, P. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0609-y · Cited by 78 · see citing works
Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor
McGray, A. R., Hallett, R. M., Bernard, D., Swift, S. L., Zhu, Z., Teoderascu, F., VanSeggelen, H., Hassell, J. A., Hurwitz, A. A., Wan, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.255 · Cited by 75 · see citing works
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
Nguyen, A., Ho, L., & Wan, Y. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00145 · Cited by 74 · see citing works
Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4 + T cells
Pommier, A., Audemard‐Verger, A., Durand, A., Lengagne, R., Delpoux, A., Martin, B., Douguet, L., Campion, A. L., Kato, M., Avril, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300314110 · Cited by 74 · see citing works
Polarization and reprogramming of myeloid-derived suppressor cells
Yang, W., Ma, G., Chen, S. H., & Pan, P. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt009 · Cited by 74 · see citing works
He, W., Liang, P., Guo, G., Huang, Z. D., Niu, Y., Dong, L., Wang, C., & Zhang, J. (2016) · Scientific Reports · doi:10.1038/srep24506 · Cited by 70 · see citing works
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.009 · Cited by 56 · see citing works
Bassett, J. D., Yang, T. C., Bernard, D., Millar, J., Swift, S. L., McGray, A. R., VanSeggelen, H., Boudreau, J. E., Finn, J. D., Parsons, R., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272336 · Cited by 48 · see citing works
Bridle, B. W., Nguyen, A., Salem, O., Zhang, L., Koshy, S. T., Clouthier, D., Chen, L., Pol, J. G., Swift, S. L., Bowdish, D. M. E., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600106 · Cited by 45 · see citing works
Zhang, L., Bridle, B. W., Chen, L., Pol, J. G., Spaner, D., Boudreau, J. E., Rosen, A., Bassett, J. D., Lichty, B. D., Bramson, J. L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438481 · Cited by 43 · see citing works
Mairhofer, D. G., Ortner, D., Tripp, C. H., Schaffenrath, S., Fleming, V., Heger, L., Komenda, K., Reider, D., Dudziak, D., Chen, S., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.241 · Cited by 28 · see citing works
Workenhe, S. T., Ketela, T., Moffat, J., Cuddington, B., & Mossman, K. L. (2015) · Oncogene · doi:10.1038/onc.2015.303 · Cited by 24 · see citing works
Pilon‐Thomas, S., & Ruffell, B. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.012 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 332 · see citing works
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
El-Sayes, N., Vito, A., & Mossman, K. L. (2021) · Cancers · doi:10.3390/cancers13040806 · Cited by 202 · see citing works
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 167 · see citing works
Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83 · see citing works
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 66 · see citing works
Yeon, M., Kim, Y., Jung, H. S., & Jeoung, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00486 · Cited by 60 · see citing works
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55 · see citing works
The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang, S., & Rabkin, S. D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1850689 · Cited by 52 · see citing works
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy
Gujar, S. A., Pol, J. G., Kumar, V., Lizarralde-Guerrero, M., Konda, P., Kroemer, G., & Bell, J. C. (2024) · Nature Protocols · doi:10.1038/s41596-024-00985-1 · Cited by 56 · see citing works
Hicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0727 · Cited by 44 · see citing works
HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma
Xu, T., Fang, Y., Gu, Y., Duo, X., Hu, T., Tao, Y., Xu, Y.-Y., Shen, H., Ma, P., & Shu, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010077 · Cited by 41 · see citing works
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Fu, Y., Peng, Y., Zhao, S., Mou, J., Zeng, L., Jiang, X., Yang, C., Huang, C., Li, Y., Yin, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689727 · Cited by 40 · see citing works
Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
Minnar, C. M., Lui, G., Gulley, J. L., Schlom, J., & Gameiro, S. R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1321318 · Cited by 28 · see citing works
Hernández, I., Rodeiro, I., Declerck, K., Herrera, J., Perez-Novo, C. A., Camp, G. V., Wever, O. D., González, K., Labrada, M., Carr, A., et al. (2021) · Marine Drugs · doi:10.3390/md19020052 · Cited by 25 · see citing works
Nguyen, A., Ho, L., Hogg, R. A., Chen, L., Walsh, S. R., & Wan, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159283 · Cited by 17 · see citing works
Chen, C., LIM, D. J., Cai, Z., Zhang, F., Liu, G., Dong, C., & Feng, Z. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113783 · Cited by 11 · see citing works
Chen, X., Wang, G., Qin, L., Hu, B., & Li, J. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08346-4 · Cited by 11 · see citing works
A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy
Burchett, R., Walsh, S. R., Wan, Y., & Bramson, J. L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.003 · Cited by 9 · see citing works
HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Nguyen, A., Brown, D., Krishnan, R., Bastin, D. J., Deng, L., Chen, L., Salem, O., Walsh, S. R., Bramson, J. L., & Wan, Y. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2181 · Cited by 8 · see citing works
Kii, S., Kitamura, H., Hashimoto, S., Ikeo, K., Ichikawa, N., Yoshida, T., Homma, S., Tanino, M., & Taketomi, A. (2022) · Inflammation Research · doi:10.1007/s00011-022-01620-z · Cited by 6 · see citing works
Sinha, D., Moseley, P., Lu, X., Wright, Q., Gabrielli, B. G., Frazer, I. H., & Cruz, J. L. G. (2022) · Cancers · doi:10.3390/cancers14246150 · Cited by 4 · see citing works
Moore, A. E., Nault, H., Cummings, D. T., Bojovic, B., Serniuck, N. J., Baker, C. L., Aarts, C. W., Venugopal, C., Singh, S. K., Hammill, J. A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112142 · Cited by 3 · see citing works
Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors
Pérez-Criado, I., Figols, M., Moya-Sevilla, A., Bautista, A., Gómez-Díaz, D., Pous, A. F., Martín-Liberal, J., & de Porras, V. R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04383-9 · Cited by 4 · see citing works
Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors
Nguyen, A., Walsh, S. R., Deng, L., Chen, L., & Wan, Y. (2025) · Advanced Science · doi:10.1002/advs.202504474 · Cited by 2 · see citing works
Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies
Lv, Y., He, C., Xie, Q., Long, F., & Fan, C. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189617 · Cited by 3 · see citing works
Functional Analysis of Tumor-Infiltrating Myeloid Cells by Flow Cytometry and Adoptive Transfer
Nguyen, A., Salem, O., & Wan, Y. (2021) · Journal of Visualized Experiments · doi:10.3791/61511 · Cited by 2 · see citing works
Chen, X., Wang, G.-J., Qin, L., Hu, B., & Li, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.28.542655
Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contractionPreprint
Burchett, R., Morris, C. G., Ishak, M., Cummings, D. T., Baker, C. L., Marius, R. M., Kazdhan, N., Silvestri, C. M., Bell, J. C., Lichty, B. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626103
Vermare, A., Ventura, A., Rouault, A., Simula, L., Seradj, M., Lhuillier, L., Weber-Delacroix, E., Mulder, K., Vimeux, L., Espie, D., et al. (2026) · bioRxiv · doi:10.64898/2026.05.28.728475
- Authors
- Nguyen, A., Ho, L., Workenhe, S. T., Chen, L., Samson, J., Walsh, S. R., Pol, J., Bramson, J. L., & Wan, Y.
- Affiliations
- McMaster University (CA)
- Corresponding author
- Wan, Yonghong
- ORCID
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 24
- Issue
- 3
- Pages
- 642-654
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2884280196
- Cited by
- 29
- References
- 67
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 3 · 2019: 1
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cell Reports (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ontario Institute for Cancer Research
- Canadian Institutes of Health Research (CIHR (FRN 123516, FRN 152954)
- Canadian Cancer Society (705143)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- histone deacetylase inhibitors, entinostat, tumor-infiltrating myeloid cells, adoptive T cell therapy, tumor antigen loss, tumor heterogeneity, tumor recurrence, M1 macrophage polarization, caspase-dependent cell death, interferon-gamma, STAT1 signaling, tumor microenvironment, immune evasion
- MeSH terms
- Interferon gamma Receptor, Animals, Antigens, Neoplasm, Antineoplastic Agents, Benzamides, Female, Immunity, Inflammation, Interferon-gamma, Melanoma, Experimental, Mice, Inbred C57BL, Phenotype, Pyridines, Signal Transduction, Immunotherapy, Adoptive, Cell Polarity, Receptors, Interferon, CD8-Positive T-Lymphocytes, Myeloid Cells, Histone Deacetylase Inhibitors, Gene Ontology, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
